Summit, N.J.-based Celgene Corp. completed the $9 billion acquisition of Juno Therapeutics Inc.
The acquisition gives Celgene access to Juno's cancer therapies, including the JCAR017 CAR-T therapy, which is in late-stage trials. With U.S. regulatory approval expected in 2019, the potential treatment for blood cancer could generate $3 billion in global peak sales.
